Recent Updates in Cardiology

Program Details

  • Intended Audience: Pharmacists interested in cardiology
  • Universal Activity Number: 0012-0000-19-015-H01-P
  • Contact Hours: 3.0
  • Program Fees: $50.00
  • Dates Available: 05/07/2019 to 05/07/2022
  • Activity Type: Application

Summary

This is an educational resource designed to help pharmacists develop a better knowledge of the recently published ACC hypertension and AHA/ACC dyslipidemia guidelines, as well as the recently published AHA/ACC/HRS focused update on atrial fibrillation.


Objectives

Module 1: Updates in Hypertension Management

The goal of this activity is to help pharmacists develop a better knowledge of the recently published ACC hypertension guidelines in order to provide safe and effective patient care.

At the completion of this activity, the participant will be able to:

  • Define the stages of hypertension and the appropriate treatment methods
  • Describe the appropriate pharmacotherapy for management of hypertension
  • Summarize the appropriateness of antihypertensive therapy in a given patient

Module 2: Updates in Dyslipidemia

The goal of this activity is to help pharmacists develop a better knowledge of the recently published AHA/ACC dyslipidemia guidelines in order to provide safe and effective patient care.

At the completion of this activity, the participant will be able to:

  • Review recent evidence-based lipid lowering guidelines.
  • Identify the mechanism of action and effect on lipids of the newly approved PCSK9 lipid lowering agents
  • Determine patient eligibility for lipid-lowering therapy
  • Select an approprite evidence-based lipid-lowering treatment plan

Module 3: Updates in Atrial Fibriliation

The goal of this activity is to help pharmacists develop a better understanding of atrial fibrillation and of the recently published AHA/ACC/HRS focused update on atrial fibrillation, in order to provide safe and effective patient care.

At the completion of this activity, the participant will be able to:

The goal of this activity is to help pharmacists develop a better understanding of atrial fibrillation and of the recently published AHA/ACC/HRS focused update on atrial fibrillation, in order to provide safe and effective patient care.

  • Describe the pathophysiology and risk factors for atrial fibrillation
  • Compare and contrast the FDA approved oral anticoagulants for management of atrial fibrillation
  • Review the 2019 AHA/ACC/HRS Focused Updates for atrial fibrillation

Acknowledgements and Disclosures

The following speakers, reviewers, and planning committee members have disclosed that he/she has no relevant financial disclosures. No one else in a position to control content has any financial relationships to disclose.

Mary Margaret Lenefsky, Pharm.D. Freelance Medical Communications Specialist/Writer

Priti Patel, Pharm.D., BCPS Clinical Associate Professor College of Pharmacy, University of Florida

Kristin Weitzel, Pharm.D., CDE, FAPhA
Associate Director, UF Health Personalized Medicine Program
Director, Continuing Pharmacy Education
Clinical Professor, Pharmacotherapy and Translational Research
University of Florida


Schedule of Activities and Requirements for Successful Course Completion

Review the course material, receive a 70% or higher on all 3 post-tests, and complete an online program evaluation.


Additional Resources

Please review the resources below before registering for the course.


ACPE logo

The University of Florida College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.